Lyndal Anderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lyndal Anderson has a total of 479 co-authors. Here are the top co-authors by number of shared publications:
- Paul Andrew Cohen
Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Perth, WA 6009, Australia
22 shared publications - Anna DeFazio
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
20 shared publications - Michael Friedlander
Prince of Wales Hospital and Royal Hospital for Women Randwick, Sydney, Australia
20 shared publications - Paul R. Harnett
Crown Princess Mary Cancer Centre Westmead Hospital Sydney New South Wales Australia
20 shared publications - Rhonda Farrell
Department of Gynaecologic Oncology Chris O'Brien Lifehouse, Camperdown Sydney New South Wales Australia
20 shared publications - Anthony J. Gill
Sydney Medical School, University of Sydney, Sydney
19 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = 178); and (D) patients with stage I MOC (n = 134), by pattern of invasion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = 178); and (D) patients with stage I MOC (n = 134), by pattern of invasion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis (n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis (n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Associations between gene expression and stage group and OS in MOC.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Associations between gene expression and stage group and OS in MOC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Overall survival in MOC by pattern of invasion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Overall survival in MOC by pattern of invasion.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Patient characteristics and analytical cohorts.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Patient characteristics and analytical cohorts.
- Open Access
- 3 July 2025
- Published by Wiley in Pathology International
- Vol. 75 (8) , 431-434
Uterine Mesenchymal Neoplasm With a Novel CDC42::PLAG1 Fusion
PLAG1 rearranged uterine mesenchymal neoplasms.
- 3 July 2025
- Published by Wiley in Pathology International
- Vol. 75 (8) , 431-434
Open AccessUterine Mesenchymal Neoplasm With a Novel CDC42::PLAG1 Fusion
PLAG1 rearranged uterine mesenchymal neoplasms.